Cachexia clinical trials

Explore recruiting cachexia clinical trials.

Recruiting cachexia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cachexia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia

France, Czechia, Romania, Italy, Germany, Poland +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

Route of nutrition and muscle wasting after oesophagectomy – a randomised, controlled, observer blind trial

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

C3651003 A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)

Bulgaria, Poland, Spain, Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

C3651021: A PHASE 2b/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Slovakia, Italy, Belgium, Germany, Spain, France +2 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss

Norway, Ireland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2, Multicenter, Randomized, Double blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants with Colorectal Cancer who have Cancer Cachexia

Czechia, Slovakia, Poland, Hungary, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

Cachexia trials by city

Cachexia in Toronto Cachexia in Vancouver Cachexia in Montreal Cachexia in Calgary Cachexia in Edmonton Cachexia in Ottawa Cachexia in Winnipeg Cachexia in Quebec City Cachexia in Hamilton Cachexia in Kitchener Cachexia in London Cachexia in Halifax Cachexia in New York Cachexia in Los Angeles Cachexia in Chicago Cachexia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease